GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kiadis Pharma NV (XAMS:KDS) » Definitions » Liabilities-to-Assets

Kiadis Pharma NV (XAMS:KDS) Liabilities-to-Assets : 1.53 (As of Dec. 2020)


View and export this data going back to 2015. Start your Free Trial

What is Kiadis Pharma NV Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Kiadis Pharma NV's Total Liabilities for the quarter that ended in Dec. 2020 was €95.68 Mil. Kiadis Pharma NV's Total Assets for the quarter that ended in Dec. 2020 was €62.76 Mil. Therefore, Kiadis Pharma NV's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2020 was 1.53.


Kiadis Pharma NV Liabilities-to-Assets Historical Data

The historical data trend for Kiadis Pharma NV's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kiadis Pharma NV Liabilities-to-Assets Chart

Kiadis Pharma NV Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Liabilities-to-Assets
Get a 7-Day Free Trial Premium Member Only 0.68 0.65 0.47 0.57 1.53

Kiadis Pharma NV Semi-Annual Data
Dec12 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20
Liabilities-to-Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.47 0.52 0.57 0.60 1.53

Competitive Comparison of Kiadis Pharma NV's Liabilities-to-Assets

For the Biotechnology subindustry, Kiadis Pharma NV's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kiadis Pharma NV's Liabilities-to-Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kiadis Pharma NV's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Kiadis Pharma NV's Liabilities-to-Assets falls into.



Kiadis Pharma NV Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Kiadis Pharma NV's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2020 is calculated as:

Liabilities-to-Assets (A: Dec. 2020 )=Total Liabilities/Total Assets
=95.681/62.762
=1.52

Kiadis Pharma NV's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2020 is calculated as

Liabilities-to-Assets (Q: Dec. 2020 )=Total Liabilities/Total Assets
=95.681/62.762
=1.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kiadis Pharma NV  (XAMS:KDS) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


Kiadis Pharma NV Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of Kiadis Pharma NV's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Kiadis Pharma NV (XAMS:KDS) Business Description

Traded in Other Exchanges
N/A
Address
Paasheuvelweg 25A, Amsterdam, NLD, 1105 BP
Kiadis Pharma NV is a Netherlands based clinical-stage biopharmaceutical company. It is focused on research, development, and commercialization of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. The company's product pipeline includes K-NK002, K-NK003, K-NK00X, and others.

Kiadis Pharma NV (XAMS:KDS) Headlines

No Headlines